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Introduction
Breast cancer is the second most common cancer in the world. While the incidence in the developing world is less than in the developed world, the incidence is increasing in sub-Saharan
Africa. [1] The estimated age standardised rate is 38.9 cases per 100 000 for the Southern Africa region, and 74.1 for the more developed world. [2] Breast cancer is the most frequent cause of cancer death among women in both the developed and developing world.
Seventy-one percent of people living with human immunodeficiency virus (HIV) live in sub-Saharan
Africa, 25% in South Africa. [3] Fifty-eight percent of these patients are women. The population of South Africa is 54 million. Approximately 10.2% of the total population and 16.8% of adults aged 15- 49 years are infected with HIV. [4] Breast cancer seems to occur less frequently in patients infected with HIV than in noninfected women. It certainly does not occur more frequently in HIV-infected patients and is classified as non-AIDS-defining. [5] The use of effective antiretroviral drugs (ARVs) has created a large population living with HIV which is susceptible to non-AIDS-defining malignancies. [5] The coincidence of breast cancer and HIV infection in the same patient is therefore common, especially in South Africa.
Curative treatment for early breast cancer is surgical combined with adjuvant chemotherapy and radiotherapy when indicated. The same three modalities are used for advanced disease with Increased toxicity and default rates have been reported for chemotherapy for breast cancer in patients with HIV infection. In a case-matched study, 55% of 52 HIV-infected patients with breast cancer treated with chemotherapy experienced adverse events compared to 30% of HIVnoninfected patients. [6] In a study of 18 HIV-infected patients with breast cancer, 4 of the 10 patients treated with chemotherapy did not complete the course due to toxicity. [7] In an older report (1988-2000) on 20 HIV-infected patients with breast cancer (of whom 10 were suffering from AIDS), 7 of 9 patients tolerated chemotherapy very poorly. [8] Very little has been published on radiotherapy tolerability in breast cancer patients with HIV infection. In Hurley et al's series HIV-infected patients tolerated local palliative radiotherapy for breast cancer well, but details were not supplied. [8] Other reports describe single cases of radiotherapy for breast cancer. [9, 10] We hypothesised that HIV-infected patients with breast cancer would experience more short-term surgical complications and would be less likely to complete adjuvant or neoadjuvant cytostatic chemotherapy and radiotherapy courses than HIV non-infected patients. In this study we prospectively compared these parameters in two groups of patients with and without HIV infection.
As secondary objectives we evaluated the effect of CD4 cell counts in HIV-infected patients on these parameters, as well as the effect of patient age and stage of disease on the occurrence or otherwise of surgical complications. The biomarker status of cancers were not evaluated in this study which focussed on operative and early postoperative outcomes.
Patients and methods
A prospective observational cohort study of patients undergoing treatment for breast cancer was performed. Specific objectives were to document the occurrence of surgical complications and the completion or noncompletion of courses of chemo-and radiotherapy in patients with or without HIV infection. 
Statistical Analysis
For the purposes of analysis, patients were grouped as HIV-infected or HIV-noninfected. Data analysis was done in STATA 13. The age of the HIV-infected and -noninfected groups was compared using an unpaired Student's t-test. Categorical variables were compared using the 2-sided Fisher exact test. Risk ratios of surgical complications were calculated for stage of disease (categorical) and patient age (continuous) variables from the incidence, using the effects command in STATA with a chi-square p value. The risk was also adjusted for patient age as a continuous variable by logistic regression yielding an odds ratio. The significance threshold for all calculations was set at 0.05. The study was considered to be exploratory in nature and no formal study sample size calculation was done. We aimed to recruit about 150 patients. This work is reported in line with the STROBE criteria. [11] 
Results
One hundred and sixty-six patients were recruited for the study. The study population is representative of patients referred for comprehensive treatment for breast cancer to state hospitals in South Africa. All consecutive patients complying with the inclusion criteria were approached for recruitment. The HIV-infected figure of 19% is similar to the 19.7% of 765 breast cancer patients tested in Soweto, Johannesburg. [12] In 6 cases the HIV status could not be determined for various reasons, and these patients were excluded from the study, leaving 160 for analysis (Table 1 ). All the patients were female and the mean age was 56 (range 29-84) years. There were 82 African patients, 65 white patients, 12 of mixed race and 1 of Indian extraction. The white population group is overrepresented: 41% vs 9% of the general population. This is probably due to the higher incidence of breast cancer in whites, older age and to easier access to tertiary medical care by the somewhat more affluent.
Thirty-one patients (19%) were HIV-infected and 129(81%) were HIV-noninfected, reflecting the consecutive recruiting method (Table 1 ). More black patients were HIV-infected (p = 0.0004). Of the 31 HIV-infected patients, 5 had CD4 counts below 200. They were all on ARVs when entered into the study, whereas only 12 (44%) of the 27 patients with CD4 counts above 200 were on ARVs. Two patients were newly-diagnosed with HIV infection when entered into the study. None of the HIVinfected patients were suffering from any AIDS-defining diseases at the time of recruitment.
There was a highly significant difference in the ages of HIV-infected (mean 41 years) and HIVnoninfected patients (mean 55 years) with a p-value of 0.0001 ( earlier stages (0, I, II) and more advanced stages (III, IV), p = 0.43 (Table 1) . HIV-infected patients therefore did not present with more advanced cancer.
One hundred and fifty-three patients (96%) underwent breast surgery (Table 2) Irrespective of HIV status, those patients who experienced local surgical complications were older than those with uncomplicated surgery, mean 58 vs 51 years. The difference was not statistically significant, p = 0.06 (Table 3) . Also, considering all patients, 12 complications occurred in patients with stages 0, I and II disease and 9 in patients with stages III and IV disease. This difference too was not significant, p = 0.78. The same was true for the racial group of patients (p = 0.63). Thus, for the whole group of patients, surgical complications were not correlated with patient age, the stage of the cancer or race. Chemotherapy was administered to 140 (88%) patients ( Table 2 ). The proportions of HIV-infected (27 of 31, 87.1%) and -noninfected (113 of 129, 87.6%) were similar, p = 1.0. Twenty-five (93%) and 106 (94%) of these patient groups respectively completed the course. There was no statistically significant difference between these proportions (p = 0.68, Table 2 ). In all cases chemotherapy consisted of standard regimens of combination 5-fluorouracil, doxorubicin and cyclophosphamide (FAC). Of the 9 patients who did not complete the course, 2 were HIV-infected. In both these cases chemotherapy was curtailed because of severe neutropaenia. One patient later completed a course of radiotherapy; the other died during the course of radiotherapy because of advanced disease. Of the 7 HIV-noninfected patients who did not complete chemotherapy, 2 defaulted, 2 died, 1 had severe neutropaenia, 1 had severe neuropathy and 1 was lost to followup. Twenty patients (4 HIVinfected) did not receive chemotherapy for various reasons: 1 had favourable in situ carcinoma, 3
had heart disease, 4 died while awaiting treatment, 7 refused chemotherapy or absconded and 5 patients were referred too late (after 84 days).
Fifty-five patients (34%) were treated with radiotherapy ( Table 2 ). The proportions of HIV-infected (14 of 31, 45%) and -noninfected (41 of 129, 32%) patients were similar, p = 0.23. Twelve (86%) and 40 (98%) of HIV infected and -noninfected patients respectively completed the course (Table 2) .
This difference was not statistically significant (p = 0.16). One HIV-infected patient had progression of disease and the other died while on radiotherapy treatment.
The CD4 cell counts of the HIV-infected patients in this study were not particularly low. The mean count for the whole group was 406 cells/µL. The mean CD4 cell counts of patients who did and did not complete adjuvant therapy courses were: chemotherapy 416 and 292 cells/µL, and radiotherapy 471 and 345 cell/µL, respectively. However, statistical analysis was not performed because of the small numbers of patients in the groups not completing therapy ( Table 2) .
Discussion
To our knowledge this is the first prospective study to address the issue of the influence of HIV infection on the outcome of the management of breast cancer. The study was conducted because of a general perception of poor healing, sepsis and intolerance to chemo-and radiotherapy in HIV-infected patients. HIV infected patients were compared to non-infected patients with regard to surgical complications and the ability to complete their courses of adjuvant therapy. We did not find a significant difference in any of these parameters between the two groups. The apparently poorer outcome of surgery was in the HIV-noninfected patients, although the difference was not statistically significant. However, the single case of a surgical complication in an HIV-infected patient and a wide risk ratio confidence interval, made the significance of this finding uncertain.
Older studies published in the 1980s and 1990s indicated higher rates of poor wound healing and sepsis in HIV-infected patients subjected to surgery. [14, 15] also reported that, in the HIV-infected patients, only a higher HI viral load and a CD4 cell count less than 50/µL was associated with more surgical complications. These two studies included many different types of surgery, both major and minor, whereas ours was on breast surgery only.
No cases of systemic sepsis or pneumonia occurred in any of our patients with or without HIV infection. This is partly due to the low rate of systemic complications that is expected in breast surgery. A large review by El-Tamer et al of data from the National Surgical Quality Improvement
Program (NSQIP) of the American College of Surgeons reported higher surgery complication rates for mastectomy than breast conservation surgery. [19] The survey found that cardiac and pulmonary complications, while more frequent in patients undergoing mastectomy than lumpectomy, were nevertheless uncommon. In fact, in their report no cardiac or pulmonary complications occurred in 1441 patients undergoing lumpectomy. There is an increased risk of venous thromboembolism in HIV-infected patients and several clinical studies have demonstrated this. [20] However, Horberg et al found no greater risk in HIV-infected than noninfected patients undergoing surgery in the antiretroviral therapy era. [16] In their study of 332 pairs of HIV-infected and -noninfected patients they found no excess of "cardiopulmonary" events in the HIV-infected group. Venous thromboembolism is not specifically reported. In the current study no instances of deep venous thrombosis or pulmonary embolism were recorded, although the cause of death in the patient who died at home after surgery is unknown.
There is some animal experimental evidence that lymphocyte depletion may delay wound healing. [21] This would therefore be a theoretical reason for poor wound healing in HIV-infected patients. This has not been demonstrated clinically. Much of the human wound healing studies in HIV infection have been done on circumcision. Rogers et al found no difference in healing time between 108 HIV-infected and 108 age-matched HIV-noninfected men after circumcision. [22] Postoperative infection delayed wound healing equally in both groups. Delayed healing in HIVinfected patients undergoing haemorrhoidectomy has been reported. [23] In our study no instances of deficient wound healing or dehiscence occurred, admittedly in a more hospitable surgical environment.
The spectre of wound sepsis looms over surgery performed on HIV-infected patients. [24, 25] However, in the current study the 14 cases of wound infection all occurred in HIV-noninfected patients. The absence of excess wound infection rates in HIV-infected patients has also been reported in comparative studies in orthopaedic [26] , cardiovascular [27] and various other types of surgery. [17] In the latter study wound infection occurred in 3.9 and 4.8% in HIV-infected and noninfected patients respectively. Our study extends these findings in patients undergoing breast surgery.
The HIV-infected patients in this study did not experience more surgical complications than the noninfected patients. In fact, the risk ratio of HIV-infection for complications was 0.20, and the odds ratio 0.23, albeit with a wide 95% confidence interval. The higher rate of surgical complications in the HIV-noninfected patients is difficult to explain. The affected patients were significantly older than the HIV-infected patients. This age difference was not unexpected as HIV infection occurs in younger people. [4] It is, nevertheless, a plausible explanation for the excess of surgical complications. However, this excess is unlikely to apply in these patients, whose mean age was only 55 years. Also, when adjusted for patient age, neither the risk ratio nor the odds ratio of HIV- While it could be speculated that the latter patient was more immunosuppressed than the other HIV-infected patients, this was not analysed statistically because of the single patient involved.
Little information is available on the outcome of cancer chemotherapy for breast cancer in HIV- HIV-infected patients treated for breast cancer. [7] In that study 4 patients could not complete their chemotherapy course. The most common toxicity was neutropaenia. Four of the 5 patients requiring delay in treatment were on PI based ARV regimens. Severe neutropaenia occurs in about one fifth of patients on FAC. [29] Therapy had to be discontinued in 3 patients in the current study due to neutropaenia, including only 2 of 27 HIV-infected patients.
Very little data is available regarding the use of radiotherapy in HIV-infected patients. There is a perception that increased radiosensitivity in these patients leads to more severe skin and mucosal toxicities. [30] This idea has however been disputed. [31] Epithelial toxicities have especially been reported in the treatment of AIDS-defining malignancies. Although the literature is scanty, radiotherapy seems to be well-tolerated by HIV infected patients with breast cancer.
Irradiation has an effect on peripheral lymphocyte counts. CD4 cells have been shown to decrease during radiation treatment of breast [32] and lung cancer. [33] This may be expected to enhance the effect of HIV on CD4 cells but has not been reported to affect the incidence of infection in HIVinfected patients treated by irradiation. [30] Our study did not show an increase in acute infection in the HIV-infected group. The study followup was too short to demonstrate the infections in which cell-mediated immunity is protective and that are common in patients with low CD4 counts.
Two HIV-infected patients did not complete their course of radiotherapy in our study. The majority therefore tolerated standard treatment courses. No dermal or mucosal toxicity was experienced by the patients in this study.
The study has some limitations. Only age and the stage of the cancer, which the authors considered to be the most apposite, were considered as possible contributing factors in the causation of surgical complications. It is possible that the prevalence of other factors such as diabetes mellitus, smoking and obesity could have differed between the two groups. The study was exploratory in nature and it is possible that a larger sample size would have been required to reject the null hypothesis. Type II errors may therefore have occurred in analysis of the data. The statistical analysis was nevertheless performed and is presented. The trend is clearly towards HIV infected patients being able to tolerate standard treatment for breast cancer.
Conclusion
This study supports the proposition that HIV-infected patients subjected to surgery for breast cancer do not experience more surgical complications than HIV-noninfected patients. Similarly they are also able to tolerate and complete the courses of chemo-and radiotherapy as do HIV-noninfected patients. In the current era of ARV use, HIV-infected patients are not generally afflicted with AIDSdefining diseases and low CD4 cell counts, and these results suggest that they can tolerate most forms of treatment for cancer well.
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